MoonLake Immunotherapeutics - 10-Q Filing
MoonLake Immunotherapeutics filed its quarterly report for the period ended March 31, 2026, disclosing financial results including a net loss of $45.7 million compared to $39.8 million in the same quarter last year. The company reported research and development expenses of $32.1 million and general and administrative expenses of $13.6 million for Q1 2026.
Tickers: $MLTX